Abstract

T cells early after neoadjuvant triple immunotherapy. Our results suggest that the addition of IL-2 can overcome resistance to neoadjuvant anti-CTLA4 + anti-PD1, providing the rationale for testing this combination as a neoadjuvant therapy in patients with early-stage cancer.

Authors	Kaptein, Paulien; Jacoberger-Foissac, Celia; Dimitriadis, Petros; Voabil, Paula; de Bruijn, Marjolein; Brokamp, Simone; Reijers, Irene; Versluis, Judith; Nallan, Gahyathiri; Triscott, Hannah; McDonald, Elizabeth; Tay, Joshua; Long, Georgina V; Blank, Christian U; Thommen, Daniela S; Teng, Michele W L
Journal	Science Translational Medicine
Pages	eabj9779
Volume	14
Date	1/01/2022
Grant ID
Funding Body
URL	http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1126/scitranslmed.abj9779